样式: 排序: IF: - GO 导出 标记为已读
-
Images in Dermatology: Dermatomyositis J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-05-06 Pelin Sagut MD, Dirk M. Elston MD
-
Weighing in on glucagon-like peptide-1 receptor agonists in dermatology J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-04-30 Warren R. Heymann MD
-
Cutaneous Manifestations of Cystic Fibrosis J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-04-30 Aaron D. Smith BS, Gabrielle Schwartzman MD, Catherine E. Lyons BS BA, Hal Flowers MD, Dana Albon MD, Kenneth Greer MD, Kevin Lonabaugh PharmD, Barrett J. Zlotoff MD
Cystic fibrosis (CF) is caused by a mutation in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene, and features recurrent sinus and pulmonary infections, steatorrhea, and malnutrition. CF is associated with diverse cutaneous manifestations, including aquagenic wrinkling of the palms, nutrient deficiency dermatoses, and vasculitis. Rarely these are presenting symptoms of CF, prior
-
Response to Nathalie Y. Ly et al., “Medical and procedural treatment of androgenetic alopecia - Where are we?” J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-04-16 Michael Buontempo BA, Ambika Nohria BA, Deesha Desai BS, Jerry Shapiro MD, Kristen Lo Sicco MD
-
Response to Moreno-Vílchez et al., “Baricitinib for the treatment of alopecia areata in adults: Real world analysis of 36 patients” J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-04-16 Deesha Desai BS, Ambika Nohria BA, Jerry Shapiro MD, Kristen Lo Sicco MD
-
HIV-related exclusion criteria in atopic dermatitis and prurigo nodularis clinical trials J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-04-13 Rebecca Leibowitz BS, Anna Fischer BA, Lauren F. Collins MD MSc, Ron J. Feldman MD PhD, Howa Yeung MD MSc
-
Leprosy J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-04-12 Rohan Manoj MBBS, Shrishti Singh MBBS, Yash Buccha MBBS, Shubham Deokar MBBS, Banyameen Iqbal MD (Pathology), Aayush Gupta MD (Dermatology)
-
-
Response to Smith and Shaw “Response to “Safety of dermatologic medications in pregnancy and lactation: An update – Part 1: Pregnancy & Part 2: Lactation”” J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-04-12 Patrick McMullan PhD, Marita Yaghi MD, Thu M. Truong PharmD, Marti Rothe MD, Jenny Murase MD, Jane M. Grant-Kels MD
-
Response to McMullan et al, “Safety of dermatologic medications in pregnancy and lactation: An Update – Part I: Pregnancy,” and Yaghi et al., “Safety of dermatologic medications in pregnancy and lactation: An Update – Part II: Lactation” J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-04-12 Nicole A. Smith MD MPH, Katharina S. Shaw MD
-
Narrowband ultraviolet B light phototherapy: A consensus on standards of care J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-04-11 Elisabeth Richard MD, Elizabeth Buzney MD, Mark Lebwohl MD, Pearl E. Grimes MD, Seemal R. Desai MD
-
Letter from the editor: Artificial intelligence and medical writing J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-04-11 Dirk M. Elston MD
-
Retrospective review of Mpox: Morphology and presentation in skin of color and sexual minorities J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-04-11 Richard W. Kim BS, Ning C. McKenzie BA, Kieron S. Leslie MBBS
-
Inpatient management of epidermolysis bullosa: Consensus-based hands-on instructions for neonates and postneonates J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-04-09 Brenda Abreu Molnar MD, Laura Levin MD, Duri Yun MD, Kimberly Morel MD, Karen Wiss MD, Julie Wieser BSN RN, Christopher Ward MD, Haley Trice BSN RN, Maria Teresa Garcia-Romero MD MPH, Allison Stephenson MPAS PA-C, Adrienne Provost BA, Harper N. Price MD, Marissa J. Perman MD, Morgan Moxon BSN RN, Beth Moeves APRN-CNP, Catherine C. McCuaig FRCPC, Christine McCarthy BSN RN TNCC ECRN, Anne W. Lucky MD
Epidermolysis bullosa (EB), characterized by skin fragility and blistering, often requires hospitalization. Training for inpatient management of EB is limited, with no unified recommendations available in North America. To develop consensus-derived best practices for hands-on inpatient management of EB in both the neonatal and postneonatal period. A modified Delphi method (expert-based input via 2
-
Response to Zhou and Yin, “Rosacea: a thermosensitive or photosensitive skin disease?” J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-04-07 Lihong Chen MD, Jie Zheng MD PhD
-
The application of circulating tumor DNA in advanced cutaneous squamous cell carcinoma: Potential opportunities and challenges J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-04-07 Hui Sun MD PhD, Wei Shen MD, Hua-Jie Zhong MD
-
Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-04-06 Mark Lebwohl MD, Joseph F. Merola MD MSc, Bruce Strober MD PhD, April Armstrong MD, Ayumi Yoshizaki MD, Paolo Gisondi MD, Balint Szilagyi PhD, Luke Peterson MS, Dirk de Cuyper MD, Nancy Cross MD, Owen Davies PhD, Alice B. Gottlieb MD PhD
Patients with psoriasis are at increased risk of liver function abnormalities. Explore rates of hepatic treatment-emergent adverse events (TEAEs) and changes in liver parameters in bimekizumab-treated patients with psoriasis. Data are reported from 5 phase 3/3b trials over 2 years. Hepatic TEAEs, laboratory elevations in alanine aminotransferase (ALT) or aspartate aminotransferase (AST), and changes
-
Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-04-06 Iraj Hasan BA, Lauren Parsons BA, Sabrina Duran BS, Zachary Zinn MD
Dupilumab, a human monoclonal antibody targeting the interleukin 4 alpha receptor, is used for treatment of moderate to severe atopic dermatitis (AD). Previous studies have reported diagnoses of cutaneous T cell lymphoma (CTCL) after dupilumab use. Investigate the risk of CTCL after dupilumab use in patients with AD. Using the TrinetX database, incidence of cutaneous and lymphoid malignancies including
-
Utility of imaging in diagnosing subungual glomus tumors: A single-center retrospective study J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-04-06 Debra K. Lee MD, Rachel C. Hill BS, Amar D. Desai MPH, Shari R. Lipner MD PhD
-
Rosacea: A thermosensitive or photosensitive skin disease? J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-04-06 ChaoJing Zhou BM, ZhiQiang Yin MD PhD
-
Low-dose oral minoxidil improves hair length and global hair density in short anagen syndrome J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-04-06 Anthony Moussa MBBS MS MSc MMed, Emadodin Darchini-Maragheh MD, Dmitri Wall MB BCh BAO MSc Health Informatics, Nekma Meah MBChB MRCP(Derm), Rodney Sinclair MBBS MD
-
Letter from the editor: First do no harm—biotin for hair and nails J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-04-06 Dirk M. Elston MD
-
Volume and distribution of radiotherapy performed by dermatologists from 2016 to 2021: A national Medicare trend analysis J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-04-04 Christian Gronbeck MD, Neelesh P. Jain MD, Albert E. Zhou MD PhD, Hao Feng MD MHS
-
Risk of lymphoma in patients with atopic dermatitis: A case-control study in the All of Us database J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-04-04 Camille M. Powers BS, Austin J. Piontkowski BS, Jeremy Orloff BA, Juliana Pulsinelli BA, Foysal B. Uddin BA, Joel Correa Da Rosa PhD, Benjamin Ungar MD, Nicholas Gulati MD PhD
-
Clinico-mycological and therapeutic updates on cutaneous dermatophytic infections in the era of Trichophyton indotineae J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-04-03 Ananta Khurana MD, Savitha Sharath MD, Kabir Sardana MD, Anuradha Chowdhary MD
has emerged as a novel dermatophyte species resulting in treatment recalcitrant skin infections. While the earliest reports came from India, has now spread to many parts of the world and is rapidly becoming a global health concern. Accurate identification of requires elaborate mycological investigations which is beyond the domain of routine microbiology testing. Extensive, non-inflammatory and atypical
-
Comparative long-term efficacy of phenol-croton oil chemical peels for persistent melasma at varied Croton tiglium oil concentrations J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-04-03 Mayra B.C. Maymone MD DSc, Fatima N. Mirza MD MPH, Denise Steiner MD PhD, Felipe Ribeiro MD, Marina Landau MD, Carolina Marçon MD PhD, Tereza C. Celidonio MD, Seaver L. Soon MD, Carlos G. Wambier MD PhD, International Peeling Society
-
-
This Month in JAAD Case Reports: June 2024 Pauci-nail lichen planus J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-04-03 Brett Sloan MD
-
Emergence of Alaskapox infection: What dermatologists need to know J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-04-02 Eva Rawlings Parker MD DTMH
-
Analysis of trends in US dermatologist density and geographic distribution J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-04-02 Milaan Shah MD, Joshua Burshtein MD, Danny Zakria MD MBA, Darrell Rigel MD MS
-
Peter J. Lynch 1936-2024. An obituary J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-04-02 Sergei A. Grando MD PhD DSc, Maria Hordinsky MD, Elizabeth Edwards MD, Christopher B. Zachary MD
-
Fearful when not feared: The plight of dermatologists in public health education for syphilis J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-04-02 Kathyana P. Santiago Mangual BA, Arianne Shadi Kourosh MD MPH
-
Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-03-29 Linda Stein Gold MD, David N. Adam MD, Lorne Albrecht MD, Javier Alonso-Llamazares MD PhD, Laura K. Ferris MD PhD, Melinda J. Gooderham MS MD, H. Chih-ho Hong MD, Steven E. Kempers MD, Leon H. Kircik MD, Mark Lebwohl MD, Wei Jing Loo BSc MBBS, Walter K. Nahm MD PhD, Kim A. Papp MD PhD, Daniel Stewart DO, Darryl P. Toth MD, Matthew Zirwas MD, David Krupa MS, Scott Snyder PharmD, Patrick Burnett MD PhD
Efficacy and/or safety profiles limit topical psoriasis treatments. Evaluate long-term effects of once-daily roflumilast cream 0.3% in patients with psoriasis. In this open-label phase 2 trial, adult patients ( = 332) with psoriasis who completed the phase 2b parent trial or were newly enrolled applied roflumilast once-daily for 52 weeks. Safety and effectiveness were assessed. Overall, 244 patients
-
Dermatologic findings associated with semaglutide use: A scoping review J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-03-29 Megan M. Tran BS, Fatima N. Mirza MD MPH, Adrian C. Lee MS, Hayley S. Goldbach MD, Tiffany J. Libby MD, Oliver J. Wisco DO
-
Patient-reported exacerbating factors for hidradenitis suppurativa: A cross sectional study J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-03-29 Rayad B. Shams BS, Christopher J. Sayed MD
-
Assuaging patient anxiety about nail biopsies with an animated educational video J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-03-29 Rachel C. Hill BS, Benedict Ho BA, Shari R. Lipner MD PhD
-
Dermatologic toxicity associated with targeted and immunotherapies in stage-IV non-small cell lung cancer patients: A 14-year cohort J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-03-29 Yanmei Peng MD PhD, Ashok V. Kumar MS, Zhong Gu MS, Nikhila Kosuru BS, Jason A. Wampfler BS, Pedro A. Reck dos Santos MD, Nathan Y. Yu MD, Jonathan D'Cunha MD PhD, Vinicius Ernani MD, Collin M. Costello MD, Ping Yang MD PhD
-
Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled, Phase 3b study J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-03-28 Kurt Gebauer MBBS, Lynda Spelman MBBS, Paul S. Yamauchi MD PhD, Jerry Bagel MD, Tushar Nishandar MD, Michael Crane PhD, Iris Kopeloff MD, Mudgal Kothekar MD MBBS, Siu-Long Yao PhD, Howard L. Sofen MD
Scalp psoriasis is common and difficult to treat. To evaluate efficacy and safety of tildrakizumab for the treatment of scalp psoriasis. In this Phase 3b, randomized, double-blind, placebo (PBO)-controlled study (NCT03897088), patients with moderate-to-severe plaque psoriasis affecting the scalp (Investigator Global Assessment modified [IGA mod] 2011 [scalp] ≥3, Psoriasis Scalp Severity Index [PSSI]
-
Drug survival of biologics in hidradenitis suppurativa: A systematic review and meta-analysis J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-03-28 James P. Pham MD, Nana A.L. Rosenø MSc, Gabriele Roccuzzo MD, Ryan C. Saal BS, Alexander Egeberg MD PhD DMSc, Hans C. Ring MD PhD, John W. Frew MBBS (Hons) MMed MS PhD
-
Elevation of creatine phosphokinase in moderate-to-severe atopic dermatitis is associated with the use of JAK inhibitors but not dupilumab: A systematic review and meta-analysis J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-03-28 Daud Manzar BHSc, Emmanuel Suntres BHSc, Nikhil Nair BSc, Yash Patel PhD, Mohannad Abu-Hilal MD
-
The divided full-thickness skin graft: A harvesting technique to optimize donor area normal skin sacrifice and closure J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-03-28 Konstantinos Seretis MD MSc PhD, Christina Telli, Ioannis D. Bassukas MD PhD
-
Ethical implications of dermatology trainees proposing alternative procedures for educational purposes J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-03-28 Helen Bian MS, Neelesh Patrick Jain MD, Jane M. Grant-Kels MD, Hao Feng MD MHS
-
Sexual dysfunction with 5-alpha-reductase inhibitor therapy for androgenetic alopecia: A global propensity score matched retrospective cohort study J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-03-28 Kyle C. Lauck MD, Allison Limmer MD, Peyton Harris BS, Dario Kivelevitch MD
-
Inflammatory linear verrucous epidermal nevus: A paradigm of progress J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-03-28 Warren R. Heymann MD
-
Correlation of clinical and trichoscopy features with the degree of histologic inflammation in lichen planopilaris and frontal fibrosing alopecia in a cross-sectional study J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-03-26 Carolina Oliveira Costa Fechine MD PhD, Neusa Yurico Sakai Valente MD PhD, Ricardo Romiti MD PhD, Maryanne Makredes Senna MD
-
Residency program unionization status and benefits: A national cross-sectional analysis of institutions with dermatology residencies J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-03-22 Ruhi Kanwar BS, Kaushik P. Venkatesh MBA MPH, Ritika Manik BS, Sofia Milosavljevic BS, Vinod E. Nambudiri MD MBA EdM
-
This month in JAAD: June 2024 J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-03-22 Dirk M. Elston MD
-
Characteristics and management of sclerosing skin diseases during immune checkpoint inhibitor therapy: An evidence-based review J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-03-21 Siddhartha Sood HBSc, Ahmed Bagit BSc, Dana Taghaddos BSc, Aliyah King BA, Khalad Maliyar MD, Muskaan Sachdeva MD, Asfandyar Mufti MD, Jensen Yeung MD
-
Lessons from a scoping review: Clinical presentations of central centrifugal cicatricial alopecia J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-03-21 Yacine N. Sow BA, Tiaranesha K. Jackson MPH, Susan C. Taylor MD, Temitayo A. Ogunleye MD
Central centrifugal cicatricial alopecia (CCCA) nomenclature describes a typical clinical presentation of cicatricial hair loss that begins on the vertex scalp with progressive, symmetric, and centrifugal evolution. However, atypical presentations have been noted clinically by the authors and reported in the literature. We sought to characterize the distribution of hair loss in published cases of adult
-
Germline cancer susceptibility in individuals with melanoma J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-03-20 Pauline Funchain MD, Ying Ni PhD, Brandie Heald MS CGC, Brandon Bungo MD, Michelle Arbesman BS, Tapas R. Behera MD, Shelley McCormick MS LCGC, Jung Min Song APRN CNS, Lucy Boyce Kennedy MD, Sarah M. Nielsen MS CGC, Edward D. Esplin MD PhD, Emily Nizialek MD PhD, Jennifer Ko MD PhD, Claudia M. Diaz-Montero PhD, Brian Gastman MD, Alexander J. Stratigos MD, Mykyta Artomov PhD, Hensin Tsao MD PhD, Joshua
Prior studies have estimated a small number of individuals with melanoma (2%-2.5%) have germline cancer predisposition, yet a recent twin study suggested melanoma has the highest hereditability among cancers. To determine the incidence of hereditary melanoma and characterize the spectrum of cancer predisposition genes that may increase the risk of melanoma. Four hundred individuals with melanoma and
-
Biologic immunomodulatory medications and autoimmune cytopenias: A cross-sectional analysis of a national surveillance database J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-03-20 Lorin A. Bibb MD, Brian D. Adkins MD, Laura D. Stephens MD, Garrett S. Booth MD MS, Jeremy W. Jacobs MD MHS
-
April 2024 iotaderma (#362) J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-03-20 Robert I. Rudolph MD FACP
-
Increased incidence of thyroid, renal, lung, melanoma, bladder, and prostate cancers after diagnosis of primary cutaneous B-cell lymphoma: A Surveillance, Epidemiology, and End Results database analysis J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-03-19 Lauren Banner BS, Thomas Z. Rohan BS, Rachel Zachian MD, Tyler Gross BS, Henry Y. Yang BS, Daniel Joffe BS, Pierluigi Porcu MD, Neda Nikbakht MD PhD
-
Histopathology and radiologic imaging for the confirmation of calciphylaxis in a diverse population: A retrospective cohort study J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-03-19 Michelle Toker BS, Nicholas Forelli BS, Olivia Wind MD, Urmi Khanna MD, Jose A. Jaller MD, Sarah Fischer MD, Edward Mardakhaev MD, Benedict Wu DO PhD
-
Dermatoscopic features and potential pitfalls of artificial intelligence-based analysis of benign acral pigmented lesions in Black patients: A multicenter observational study J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-03-19 Mariela Mitre MD PhD, Sharif Hosein BSc, Andia Mitri MD, Nicholas R. Kurtansky BSc, Silvia E. Mancebo MD, Maira Fonseca MD, Ashley Keyes Jacobs MD, Veronica Rotemberg MD PhD, Michael A. Marchetti MD
-
Evaluation of the measurement properties and validation of the Skindex-16 among patients with acne J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-03-19 Ali Shields BS, Suephy C. Chen MD MS, Manraj N. Kaur PhD, Donna Rowen PhD MSc, Alison Layton MBChB, Diane Thiboutot MD, Jerry Tan MD, John S. Barbieri MD MBA
-
PIDASI and PIHASI: Scoring tools for assessment of postinflammatory hyperpigmentation J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-03-19 Michelle Lazar BS, Shawn Shih MD, Susruthi Rajanala MD, Henriette De La Garza MD, Kevin F. Kennedy MSc, Neelam A. Vashi MD
-
Attenuation of disease process following treatment with low-dose naltrexone in patients with frontal fibrosing alopecia and lichen planopilaris: A retrospective study J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-03-19 Selina M. Yossef BA, Joseph C. English III MD
-
Response to Neale et al., “Guidance on screening magnetic resonance imaging decisions for congenital melanocytic nevi” J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-03-18 Arunachalam Narayanan MD DNB PDCC
-
Executive Summary: From the Medical Board of the National Psoriasis Foundation: Perioperative management of immunomodulatory agents in patients with psoriasis and psoriatic arthritis J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-03-17 Warren A. James MD, Angela L. Rosenberg BS, Jashin J. Wu MD, Sylvia Hsu MD, April Armstrong MD MPH, Elizabeth B. Wallace MD, Lara Wine Lee MD PhD, Joseph Merola MD MMSc, Sergio Schwartzman MD, Dafna Gladman MD, Clive Liu MD, John Koo MD, Jason E. Hawkes MD MS, Soumya Reddy MD, Ron Prussick MD FRCPC, Paul Yamauchi MD, Michael Lewitt MD, Jennifer Soung MD, Jeffery Weinberg MD, Mark Lebwohl MD, Brad Glick
Systemic immunomodulatory agents are indicated in the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis. Perioperative use of these medications may increase the risk of surgical site infection and complication. To evaluate the risk of surgical site infection and complication in patients with chronic autoimmune inflammatory disease receiving immunomodulatory agents (tumor necrosis